The LAPSE trial, sponsored by Walter Reed National Military Medical Center, explores the efficacy of levetiracetam in alleviating neuropsychiatric symptoms in Alzheimer's disease patients with seizure-like activity. Given the increasing recognition of seizures in Alzheimer's patients, this study could position levetiracetam as a dual-action therapy addressing both cognitive decline and neuropsychiatric symptoms. The market for Alzheimer's treatments is substantial, with a growing demand for therapies that can improve quality of life. If successful, this trial could enhance levetiracetam's marketability beyond its current use as an anti-epileptic drug, potentially leading to expanded indications and increased revenue streams. Competitive implications include the need to monitor other emerging therapies targeting neuropsychiatric symptoms in dementia.